A global treatments for coronaviruses including COVID-19.
Bahman YousefiSaeid ValizadehHadi GhaffariAzadeh VahediMohsen KarbalaeiMajid EslamiPublished in: Journal of cellular physiology (2020)
In late December 2019 in Wuhan, China, several patients with viral pneumonia were identified as 2019 novel coronavirus (2019-nCoV). So far, there are no specific treatments for patients with coronavirus disease-19 (COVID-19), and the treatments available today are based on previous experience with similar viruses such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Influenza virus. In this article, we have tried to reach a therapeutic window of drugs available to patients with COVID-19. Cathepsin L is required for entry of the 2019-nCoV virus into the cell as target teicoplanin inhibits virus replication. Angiotensin-converting-enzyme 2 (ACE2) in soluble form as a recombinant protein can prevent the spread of coronavirus by restricting binding and entry. In patients with COVID-19, hydroxychloroquine decreases the inflammatory response and cytokine storm, but overdose causes toxicity and mortality. Neuraminidase inhibitors such as oseltamivir, peramivir, and zanamivir are invalid for 2019-nCoV and are not recommended for treatment but protease inhibitors such as lopinavir/ritonavir (LPV/r) inhibit the progression of MERS-CoV disease and can be useful for patients of COVID-19 and, in combination with Arbidol, has a direct antiviral effect on early replication of SARS-CoV. Ribavirin reduces hemoglobin concentrations in respiratory patients, and remdesivir improves respiratory symptoms. Use of ribavirin in combination with LPV/r in patients with SARS-CoV reduces acute respiratory distress syndrome and mortality, which has a significant protective effect with the addition of corticosteroids. Favipiravir increases clinical recovery and reduces respiratory problems and has a stronger antiviral effect than LPV/r. currently, appropriate treatment for patients with COVID-19 is an ACE2 inhibitor and a clinical problem reducing agent such as favipiravir in addition to hydroxychloroquine and corticosteroids.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- angiotensin converting enzyme
- acute respiratory distress syndrome
- end stage renal disease
- inflammatory response
- angiotensin ii
- newly diagnosed
- ejection fraction
- prognostic factors
- chronic kidney disease
- cardiovascular events
- peritoneal dialysis
- lipopolysaccharide induced
- stem cells
- risk factors
- type diabetes
- single cell
- transcription factor
- mental health
- toll like receptor
- antiretroviral therapy
- mechanical ventilation
- combination therapy
- bone marrow
- mesenchymal stem cells